 | ||
| These Could Be the Best Stocks of the Year Zacks Member, This is your chance to get into 7 Biotech stocks with triple-digit profit potential – and I don't want you to miss out. Our recent recommendations in this sector soared as much as +205%, +258%, even +477% within just a matter of months.¹ Scientists and doctors are developing radical treatments for thousands of diseases that were considered uncurable – including many types of cancers, muscular dystrophy, and HIV/AIDS. Not only are they creating cures, they're finding ways to edit human DNA to literally erase our vulnerability to these diseases. In the process, the Biotech sector is projected to surge beyond $2.4 trillion by 2028. Seven stocks in particular are poised for strong upside in the coming year, including one company that multiplied its revenue 10X last year… and looks ready to do it again as it begins developing vaccines… for cancer. Advances in the medical field have been coming faster than ever before… and we believe these stocks could explode higher at any moment. That means there's no time to waste. Our resident biotech expert Kevin Cook reveals the names of these 7 breakthrough stocks in his new Special Report, The Century of Biology (3rd Edition). But don't delay – this report is only available until midnight tonight (Sunday, March 28). Regards,
| ||
 | ||
| ¹ The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors and may represent the partial close of a position. This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or US investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through March 1, 2021. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank #1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed above. Zacks Emails Zacks Investment Research |
没有评论:
发表评论